1. Home
  2. RVMDW vs GALT Comparison

RVMDW vs GALT Comparison

Compare RVMDW & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RVMDW
  • GALT
  • Stock Information
  • Founded
  • RVMDW N/A
  • GALT 2000
  • Country
  • RVMDW United States
  • GALT United States
  • Employees
  • RVMDW 443
  • GALT N/A
  • Industry
  • RVMDW
  • GALT Biotechnology: Pharmaceutical Preparations
  • Sector
  • RVMDW
  • GALT Health Care
  • Exchange
  • RVMDW Nasdaq
  • GALT Nasdaq
  • Market Cap
  • RVMDW N/A
  • GALT N/A
  • IPO Year
  • RVMDW N/A
  • GALT N/A
  • Fundamental
  • Price
  • RVMDW $0.76
  • GALT $3.00
  • Analyst Decision
  • RVMDW
  • GALT Strong Buy
  • Analyst Count
  • RVMDW 0
  • GALT 1
  • Target Price
  • RVMDW N/A
  • GALT $11.00
  • AVG Volume (30 Days)
  • RVMDW N/A
  • GALT 128.9K
  • Earning Date
  • RVMDW N/A
  • GALT 11-15-2024
  • Dividend Yield
  • RVMDW N/A
  • GALT N/A
  • EPS Growth
  • RVMDW N/A
  • GALT N/A
  • EPS
  • RVMDW N/A
  • GALT N/A
  • Revenue
  • RVMDW N/A
  • GALT N/A
  • Revenue This Year
  • RVMDW N/A
  • GALT N/A
  • Revenue Next Year
  • RVMDW N/A
  • GALT N/A
  • P/E Ratio
  • RVMDW N/A
  • GALT N/A
  • Revenue Growth
  • RVMDW N/A
  • GALT N/A
  • 52 Week Low
  • RVMDW N/A
  • GALT $1.56
  • 52 Week High
  • RVMDW N/A
  • GALT $4.27
  • Technical
  • Relative Strength Index (RSI)
  • RVMDW N/A
  • GALT 70.75
  • Support Level
  • RVMDW N/A
  • GALT $2.52
  • Resistance Level
  • RVMDW N/A
  • GALT $2.65
  • Average True Range (ATR)
  • RVMDW 0.00
  • GALT 0.13
  • MACD
  • RVMDW 0.00
  • GALT 0.05
  • Stochastic Oscillator
  • RVMDW 0.00
  • GALT 91.68

About RVMDW Revolution Medicines Inc. Warrant

Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.

Share on Social Networks: